Biotech Stocks Surge in After-Hours Trading on Positive Trial Updates and Data Momentum
ByAinvest
Tuesday, Oct 14, 2025 12:04 am ET1min read
ACET--
Processa Pharmaceuticals Inc. (PCSA) saw its shares surge 40.3% in after-hours trading, closing at $0.51 after a regular session gain of 29% to $0.36. The sharp move was characterized by unusually high volume, with over 200 million shares traded, far above its average of 8.74 million shares. While no fresh company-specific news was reported, the move appears to be driven by speculative momentum [1].
Palisade Bio Inc. (PALI) rose 11.9% in after-hours trading, climbing to $1.88 following a regular session loss of 11.81% to $1.68. The rebound can be attributed to recent volatility tied to clinical trial updates and a major capital raise. Palisade closed a $138 million upsized public offering, which included the full exercise of its over-allotment option, one day after pricing a $120 million underwritten offering. The company's October 1 announcement of a 100% clinical response in its Phase 1b trial for ulcerative colitis and Health Canada's approval to initiate trials for fibrostenotic Crohn's disease added further momentum to its pipeline narrative [1].
Q32 Bio Inc. (QTTB) rose 26.6% in after-hours trading, climbing to $3.19 after a strong regular session that saw the stock gain 16.1% to close at $2.52. The move appears speculative ahead of the company's scheduled earnings report in November, with no new press releases or filings issued during the day [1].
Additional biotech stocks that saw significant after-hours gains include Telomir Pharmaceuticals (TELO), Reviva Pharmaceuticals (RVPH), NeuroOne Medical Technologies (NMTC), and BioRestorative Therapies (BRTX). These stocks experienced notable gains due to renewed interest in recent company updates, speculative trading, and clinical trial data momentum [2].
ACIU--
ACRV--
ADAG--
ADVM--
Biotech stocks surged after hours on trial updates and data momentum. SOPHiA GENETICS, SELLAS Life Sciences, Ironwood Pharmaceuticals, Spectral AI, Adverum Biotechnologies, AC Immune, Senti Biosciences, Vivos Therapeutics, Mangoceuticals, InflaRx, Talkspace, MDxHealth, Acrivon Therapeutics, Gain Therapeutics, Alpha Teknova, Tenaya Therapeutics, Eledon Pharmaceuticals, Fate Therapeutics, Adicet Bio, Tectonic Therapeutic, Galecto, Adagene, Skye Bioscience, Ginkgo Bioworks, LENZ Therapeutics, and Gossamer Bio saw significant gains.
Several small-cap biotech stocks experienced significant after-hours gains on Tuesday, driven by renewed interest in recent clinical trial updates and data momentum. The notable movers include Processa Pharmaceuticals (PCSA), Palisade Bio (PALI), and Q32 Bio (QTTB), among others.Processa Pharmaceuticals Inc. (PCSA) saw its shares surge 40.3% in after-hours trading, closing at $0.51 after a regular session gain of 29% to $0.36. The sharp move was characterized by unusually high volume, with over 200 million shares traded, far above its average of 8.74 million shares. While no fresh company-specific news was reported, the move appears to be driven by speculative momentum [1].
Palisade Bio Inc. (PALI) rose 11.9% in after-hours trading, climbing to $1.88 following a regular session loss of 11.81% to $1.68. The rebound can be attributed to recent volatility tied to clinical trial updates and a major capital raise. Palisade closed a $138 million upsized public offering, which included the full exercise of its over-allotment option, one day after pricing a $120 million underwritten offering. The company's October 1 announcement of a 100% clinical response in its Phase 1b trial for ulcerative colitis and Health Canada's approval to initiate trials for fibrostenotic Crohn's disease added further momentum to its pipeline narrative [1].
Q32 Bio Inc. (QTTB) rose 26.6% in after-hours trading, climbing to $3.19 after a strong regular session that saw the stock gain 16.1% to close at $2.52. The move appears speculative ahead of the company's scheduled earnings report in November, with no new press releases or filings issued during the day [1].
Additional biotech stocks that saw significant after-hours gains include Telomir Pharmaceuticals (TELO), Reviva Pharmaceuticals (RVPH), NeuroOne Medical Technologies (NMTC), and BioRestorative Therapies (BRTX). These stocks experienced notable gains due to renewed interest in recent company updates, speculative trading, and clinical trial data momentum [2].

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet